All In Biotech

Drug Trial Radar · NCT06245915

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

37

Actual

Start

Feb 26, 2024

Primary completion

Dec 31, 2026

Study completion Jun 30, 2028

Sponsor

Lead sponsor
Arsenal Biosciences, Inc.Industry
Sponsor type
Industry
First posted
Feb 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.

Conditions

  • Advanced/Metastatic Clear Cell Renal Cell Carcinoma
  • Recurrence

Interventions

  • AB-2100Biological

    autologous T cell therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 (Dose escalation): incidence of adverse eventsTime frame: From AB-2100 infusion up to 21 days post infusion
  2. Phase 2 (Cohort expansion): Objective response rate (ORR)Time frame: From AB-2100 infusion up to 24 months post-infusion

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • Moffitt Cancer Center

    Tampa, Florida

  • University of Iowa and Holden Comprehensive Cancer Center

    Iowa City, Iowa

  • Dana Farber Cancer Institue

    Boston, Massachusetts

  • Perlmutter Cancer Center - NYU Langone Health

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute - Univ of Utah Health

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.